A Multi-center, Randomized, Controlled, Open-label Phase II/III Clinical Trial to Investigate Whether Transarterial Tirapazamine Injection Followed by Transarterial Embolization (TATE) is Superior to Traditional Transarterial Chemoembolization (TACE) in Patients With Intermediate-Stage Hepatocellular Carcinoma (HCC)
Latest Information Update: 09 Apr 2025
At a glance
- Drugs Tirapazamine (Primary) ; Epirubicin
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Sponsors Zhejiang Raygene Pharmaceuticals
Most Recent Events
- 06 Apr 2025 Status changed from not yet recruiting to recruiting.
- 04 Mar 2025 New trial record